Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PROK
stocks logo

PROK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
-111.75K
-247.04%
-0.151
-11.01%
0.00
-100%
-0.160
+23.08%
--
--
-0.170
+30.77%
Estimates Revision
The market is revising Upward the revenue expectations for ProKidney Corp. (PROK) for FY2025, with the revenue forecasts being adjusted by 12.23% over the past three months. During the same period, the stock price has changed by 14.22%.
Revenue Estimates for FY2025
Revise Upward
up Image
+12.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+13.8%
In Past 3 Month
Stock Price
Go Up
up Image
+14.22%
In Past 3 Month
Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is 4.67 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is 4.67 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
1 Sell
Hold
Current: 2.570
sliders
Low
1.00
Averages
4.67
High
10.00
Current: 2.570
sliders
Low
1.00
Averages
4.67
High
10.00
UBS
Buy
upgrade
$4 -> $8
2025-07-15
Reason
UBS
Price Target
$4 -> $8
2025-07-15
upgrade
Buy
Reason
UBS raised the firm's price target on ProKidney to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel show stabilization of kidney function in patients with diabetes and advanced chronic kidney disease, the analyst tells investors in a research note. ProKidney expects to meet with the FDA in the near-term to align on eGFR slope as a potential acceptable Phase 3 surrogate endpoint for accelerated approval in advanced CKD, which should give clarity on a potential readout.
Guggenheim
Buy
maintain
$6 -> $7
2025-07-14
Reason
Guggenheim
Price Target
$6 -> $7
2025-07-14
maintain
Buy
Reason
Guggenheim raised the firm's price target on ProKidney to $7 from $6 and keeps a Buy rating on the shares. Guggenheim says it was "very surprised" by the move in ProKidney shares last week following an "encouraging but somewhat incremental" data release on Tuesday from the rilparencel Phase 2 REGEN-007 trial, and tells investors in a research note that the firm was surprised by the enthusiasm experts showed for rilparencel following this data update. The firm awaits next month's regulatory update after the company's Type B Meeting with the FDA, and the full REGEN-007 data presentation at the American Society of Nephrology Meeting in November.
Citi
Buy
upgrade
$6 -> $9
2025-07-08
Reason
Citi
Price Target
$6 -> $9
2025-07-08
upgrade
Buy
Reason
Citi raised the firm's price target on ProKidney to $9 from $6 and keeps a Buy rating on the shares after the company reported results from the Phase 2 REGEN-007 study evaluating rilparencel in diabetes and chronic kidney disease. The firm says the initial data exceeded Citi's and management's expectations. REGEN-007 demonstrated statistically significant efficacy in group one, which may support accelerated approval in Phase 3 pending FDA confirmation, the analyst tells investors in a research note. Citi upped its probability of sucess for REGEN-007 to 60% from 50%.
BofA
Jason Gerberry
Neutral -> Underperform
downgrade
$3 -> $1
2025-06-30
Reason
BofA
Jason Gerberry
Price Target
$3 -> $1
2025-06-30
downgrade
Neutral -> Underperform
Reason
BofA analyst Jason Gerberry downgraded ProKidney to Underperform from Neutral with a price target of $1, down from $3.
BofA
Neutral -> Underperform
downgrade
$3 -> $1
2025-06-30
Reason
BofA
Price Target
$3 -> $1
2025-06-30
downgrade
Neutral -> Underperform
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Prokidney Corp (PROK.O) is -4.01, compared to its 5-year average forward P/E of -5.42. For a more detailed relative valuation and DCF analysis to assess Prokidney Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.42
Current PE
-4.01
Overvalued PE
-0.46
Undervalued PE
-10.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.82
Undervalued EV/EBITDA
-10.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
-16.64
Current PS
0.00
Overvalued PS
833.83
Undervalued PS
-867.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 503.05% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 503.05% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PROK News & Events

Events Timeline

(ET)
2025-11-10
16:52:00
ProKidney Announces Q3 EPS of 12 Cents, Below Consensus Estimate of 14 Cents
select
2025-11-06 (ET)
2025-11-06
11:03:00
ProKidney Reveals Findings from Phase 2 REGEN-007 Trial of Rilparencel
select
2025-08-12 (ET)
2025-08-12
16:15:12
ProKidney reports Q2 EPS (13c), consensus (14c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-11NASDAQ.COM
PROKIDNEY CORP. Reports Smaller Q3 Loss, Surpassing Expectations

  • Earnings Report: PROKIDNEY CORP. reported a loss of $16.47 million for the third quarter, an improvement from a loss of $17.91 million in the same period last year.

  • Earnings Per Share: The company's earnings per share (EPS) were -$0.12, compared to -$0.14 in the previous year, beating analysts' expectations of -$0.14 per share.

[object Object]
Preview
9.5
11-11Newsfilter
ProKidney Announces Financial Results for Q3 2025 Along with Regulatory and Clinical Updates

  • Phase 2 Study Results: ProKidney Corp. presented full results from the Phase 2 REGEN-007 study at ASN Kidney Week 2025, showing that rilparencel significantly improved kidney function in patients with advanced chronic kidney disease (CKD) and diabetes, with 63% of patients meeting key inclusion criteria for the ongoing Phase 3 PROACT 1 study.

  • Phase 3 PROACT 1 Update: The FDA has confirmed that the eGFR slope can be used as a surrogate endpoint for the accelerated approval of rilparencel, with more than half of the required patients enrolled and topline results expected in Q2 2027.

  • Financial Position: As of September 30, 2025, ProKidney reported $272 million in cash and equivalents, sufficient to fund operations into mid-2027, while also noting a decrease in research and development expenses compared to the previous year.

  • Chronic Kidney Disease Context: CKD affects approximately 37 million adults in the U.S., with diabetes being the leading cause; ProKidney aims to address the unmet need for effective treatments in patients with advanced CKD and diabetes through its innovative cell therapy, rilparencel.

[object Object]
Preview
9.0
11-07Newsfilter
ProKidney Unveils Comprehensive Findings from Phase 2 REGEN-007 Trial of Rilparencel at the 2025 American Society of Nephrology Kidney Week

  • Rilparencel's Efficacy: In a Phase 2 trial, rilparencel significantly slowed the progression of chronic kidney disease (CKD) in patients with diabetes, showing a 78% improvement in the annual decline of estimated glomerular filtration rate (eGFR) in one treatment group.

  • Safety Profile: The treatment was well tolerated with no serious adverse events related to rilparencel, maintaining a safety profile consistent with previous studies.

  • Phase 3 Study Update: ProKidney's ongoing Phase 3 PROACT 1 study has enrolled over half of the required patients, with topline results expected in Q2 2027, as the FDA has confirmed eGFR slope as an acceptable endpoint for accelerated approval.

  • Significance of Rilparencel: Rilparencel is the only cell therapy currently in a Phase 3 clinical study for CKD and type 2 diabetes, representing a potential novel treatment option for patients facing limited therapeutic alternatives.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Prokidney Corp (PROK) stock price today?

The current price of PROK is 2.57 USD — it has increased 4.47 % in the last trading day.

arrow icon

What is Prokidney Corp (PROK)'s business?

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

arrow icon

What is the price predicton of PROK Stock?

Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is 4.67 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Prokidney Corp (PROK)'s revenue for the last quarter?

Prokidney Corp revenue for the last quarter amounts to 217.00K USD, decreased % YoY.

arrow icon

What is Prokidney Corp (PROK)'s earnings per share (EPS) for the last quarter?

Prokidney Corp. EPS for the last quarter amounts to -0.12 USD, decreased -14.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Prokidney Corp (PROK)'s fundamentals?

The market is revising Upward the revenue expectations for ProKidney Corp. (PROK) for FY2025, with the revenue forecasts being adjusted by 12.23% over the past three months. During the same period, the stock price has changed by 14.22%.
arrow icon

How many employees does Prokidney Corp (PROK). have?

Prokidney Corp (PROK) has 204 emplpoyees as of December 05 2025.

arrow icon

What is Prokidney Corp (PROK) market cap?

Today PROK has the market capitalization of 773.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free